Early Intervention for Schizophrenia on the Horizon: Implications for Clinicians and Patients – Psychiatric Times
By Carlos A. Larrauri, MSN and Alessio Travaglia, PhD
Schizophrenia is one of the most recognized yet least understood chronic brain disorders. The estimates of the international prevalence of schizophrenia among noninstitutionalized individuals are 0.33% to 0.75%. Schizophrenia is complex and characterized by substantial biological and clinical heterogeneity that varies significantly from person to person, leading to missed diagnosis and conflation with other diseases or drug use.
For instance, psychosis is a hallmark trait of schizophrenia but it may also be present in other clinical conditions, such as posttraumatic stress disorder, bipolar disorder, major depression, certain personality disorders and delusional disorders. Furthermore, stimulant and cannabis use as well as psychedelics can cause individuals to have temporary psychosis-like symptoms.
Schizophrenia is often associated with delusions and hallucinations but also with marked cognitive impairment and less recognized negative symptoms, such as social withdrawal and diminished emotional expression. Additionally, clinicians may interview and care for patients who may suffer from anosognosia or are unaware they are ill. This “lack of insight” may lead to difficulty obtaining an accurate history or to conflicting reports between patients and their family members advocating for them to get help. Moreover, some research has shown a disparate diagnosis of schizophrenia among minoritized groups that fail to reflect an increased prevalence, highlighting racial disparities in mental health care.